Medications prescribed among the cohort of participants at risk of CKD were generally similar to the CKD cohort, except for more common use of insulin (83 363 [16.3%]) among those with diabetes and of NSAIDs (701 493 [35.5%]) and PPIs (295 804 (15.0%]) overall (eTable 6 in the Supplement). This evidence concerns the gene INS and diabetes mellitus.